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1Heart failure in hypertrophic cardiomyopathy (HCM) is most common because of mechanical impedance to left ventric-
ular (LV) outflow, present in up to 70% of patients at rest or with 
physiological provocation, and produced by mitral valve systolic 
anterior motion with associated mitral regurgitation, resulting in 
elevated LV pressures and left atrial hypertension.1,2 However, 
the prevalence, clinical significance, and management impli-
cations of pulmonary hypertension and the associated risk for 
adverse outcomes in patients with HCM are incompletely under-
stood. Previous reports characterizing pulmonary artery pressure 
(PAP) dynamics in patients with obstructive HCM have relied 
largely on estimates derived from Doppler echocardiography 
studies and attributed adverse consequences (ie, all-cause mor-
tality) to pulmonary hypertension.3,4 Therefore, in the present 
analysis, we have revisited clinical issues surrounding pulmo-
nary hypertension in a unique cohort of patients with HCM 
using hemodynamic data obtained at cardiac catheterization.
See Clinical Perspective
Methods
Study Population
We evaluated 187 consecutive adult patients diagnosed with obstruc-
tive HCM who underwent right heart catheterization and subsequent 
Original Article
© 2017 American Heart Association, Inc.
Circ Heart Fail is available at http://circheartfailure.ahajournals.org DOI: 10.1161/CIRCHEARTFAILURE.116.003689
Background—There are limited data on the prevalence, pathophysiology, and management implications of pulmonary 
hypertension in patients with obstructive hypertrophic cardiomyopathy and advanced heart failure.
Methods and Results—To assess the clinical significance of measured cardiopulmonary hemodynamics in hypertrophic 
cardiomyopathy patients with heart failure, we retrospectively assessed right heart catheterization data in 162 consecutive 
patients with outflow tract gradients (median [interquartile range], 90 mm Hg [70–110 mm Hg]), 59±11 years old, and 
49% men, predominately New York Heart Association class III/IV status. Pulmonary hypertension (mean pulmonary artery 
pressure, ≥25 mm Hg) was present in 82 patients (51%), including 29 (18%) regarded as moderate-severe (mean pulmonary 
artery pressure, ≥35 mm Hg) and 28 (34%) also had increased pulmonary vascular resistance >3.0 WU. The pulmonary artery 
wedge pressure was ≤15 mm Hg in 54%, indicating that left atrial hypertension was absent in a majority of patients. Notably, 
9 patients (11%) met hemodynamic criteria for precapillary pulmonary hypertension (mean pulmonary artery pressure, ≥25 
mm Hg; pulmonary vascular resistance, >3.0 WU; pulmonary artery wedge pressure, ≤15 mm Hg). Over a median follow-up 
of 327 days (90–743 days) after surgical myectomy (or alcohol septal ablation), 92% and 95% of patients with or without 
preoperative pulmonary hypertension, respectively, were asymptomatic or mildly symptomatic. One postoperative death 
occurred in a 59-year-old woman with acute respiratory failure and mean pulmonary artery pressure of 65 mm Hg.
Conclusions—Pulmonary hypertension was common in obstructive hypertrophic cardiomyopathy patients with advanced 
heart failure. Although possibly a contributor to preoperative heart failure, pulmonary hypertension did not significantly 
influence clinical and surgical outcome. Notably, a novel patient subgroup was identified with resting invasive 
hemodynamics consistent with pulmonary vascular disease.  (Circ Heart Fail. 2017;10:e003689. DOI: 10.1161/
CIRCHEARTFAILURE.116.003689.)
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septal reduction with surgical myectomy or percutaneous alcohol 
septal ablation at Tufts Medical Center 2009 to 2015. Diagnosis of 
HCM was based on echocardiographic or cardiovascular magnetic 
resonance imaging evidence of LV hypertrophy (wall thickness, ≥15 
mm) involving ≥1 segment of the chamber in the absence of a car-
diac or systemic disease capable of producing the extent of hypertro-
phy evident. Twenty-five patients were excluded from this analysis 
because of moderate or severe mitral or aortic disease unrelated to 
HCM, and the final study group comprised 162 patients. This study 
has been reviewed and approved by Institutional Review Boards of 
Tufts Medical Center (12019) for retrospective collection of data for 
this project; the requirement of informed consent was waived for all 
patients.
Echocardiography
Transthoracic echocardiography was performed using commercially 
available instruments. Measurements of LV wall thickness and cav-
ity dimensions, ejection fraction, and LV outflow tract gradient (es-
timated with continuous wave Doppler) were obtained as reported 
previously.5 Mitral regurgitation was graded mild, moderate, and se-
vere using semiquantitative criteria. Left atrial volume was calculated 
with the biplane area-length method and indexed to body surface 
area. Patients with LV outflow tract gradient of zero or <50 mm Hg 
under resting conditions underwent stress echocardiography with up-
right exercise on a symptom-limited Bruce protocol; subaortic gradi-
ent was assessed at baseline and immediately after exercise in the 
supine position. Measurements of right ventricular (RV) diameter and 
systolic function including fractional area change and peak systolic 
tricuspid annular velocity (S′) were measured according to standard 
published guidelines.6
Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging studies were performed in 
118 of the 162 HCM study patients (73%) using a 1.5 T clinical 
scanner. Cine sequences were performed in standard views with 
full LV coverage. Late gadolinium enhancement (LGE) images 
were acquired 10 to 15 minutes after intravenous administration 
of 0.2-mmol/kg gadolinium-DTPA using breath-held segmented 
inversion-recovery sequence. LGE quantification was performed 
by manually adjusting grayscale threshold to visually define LGE, 
which were summed and expressed as proportion of total LV 
myocardium.7
Cardiac Catheterization
Each patient underwent right heart catheterization in the supine posi-
tion at rest, either as part of the premyectomy clinical evaluation or 
at the time of alcohol septal ablation. Most patients continued to take 
medications that had been administered previously for the purpose 
of controlling symptoms of heart failure (eg, β-adrenergic receptor 
blockers or verapamil).
Right atrial, mean PAP (mPAP), and pulmonary artery wedge 
pressure (PAWP) were measured at end-expiration and averaged over 
≥3 beats. Cardiac output, measured in 157 patients, was determined 
by the thermodilution (n=150) or assumed Fick (n=7) methods, and 
indexed to body surface area. Pulmonary vascular resistance was cal-
culated as (mPAP−PAWP)/cardiac output, transpulmonary gradient 
was calculated as mPAP−PAWP, and diastolic pressure gradient was 
calculated as (diastolic PAP–PAWP).
Statistical Analysis
Continuous data are expressed as mean±SD for normally distributed 
variables or as median (interquartile range) for non-normally distrib-
uted variables. Comparisons between normally distributed groups 
were performed by Student t test. The Mann–Whitney or Kruskal–
Wallis tests were used for comparisons between non-normally dis-
tributed variables. Exact χ2 test was used for categorical variables. All 
tests were 2 tailed, and statistical significance was defined by P<0.05. 
All analyses were performed using R version 3.2.5.8
Results
Study Population
The 162 study patients with obstructive HCM and septal 
reduction therapy (surgical myectomy in 116 and alcohol sep-
tal ablation in 46) were aged 35 to 82 years (mean, 59±11 
years) and 79 (49%) were men (Table 1). Maximum LV wall 
thickness was 19±4 mm and LV outflow obstruction (≥30 
mm Hg) was present at rest (n=125) or after physiological 
provocation (n=37) in all patients, with peak systolic gradients 
of 50 to 160 mm Hg (average 90 mm Hg).
Patients were severely symptomatic, consistent with New 
York Heart Association functional class III/IV, and refractory 
to maximum medical management before septal reduction. 
Moderate to severe mitral regurgitation was present in 30 patients 
(19%), associated with increased left atrial volume (≥34 mL/m2) 
in 28 patients; LV ejection fraction ranged from 48% to 80% 
(mean, 65%). Thirty-six patients (22%) had ≥1 episode of symp-
tomatic atrial fibrillation. Obstructive atherosclerotic coronary 
artery disease was present in 22 patients (14%). The average RV 
diameter (37 mm [33–42 mm]), RV fractional area change (47 
[43–51] % change), and peak tricuspid annulus S′ velocity (12.3 
cm/s [11.0–14.0 cm/s]) were within the range of normal.
Group Hemodynamic Profile
Among the 162 study patients, mPAP ranged from 11 to 
65 mm Hg (median 25 [20-31] mm Hg); 82 patients (51%) 
were judged to have pulmonary hypertension with mPAP 
≥25 mm Hg. Of these, 36 had 25 to 30 mm Hg, 19 had 31 to 
35 mm Hg, 9 had 36 to 40 mm Hg, and 18 had >40 mm Hg 
(Figure 1). Of the 82 patients with increased PAP, 28 (34%) 
also had increased pulmonary vascular resistance (>3.0 WU). 
The average pulmonary artery systolic pressure for the entire 
cohort was 41 mm Hg (31–46 mm Hg).
The mPAP did not correlate with peak LV outflow tract 
gradient (r=0.09; P=0.32; Figure 2). Correlation between 
systolic PAP measured at catheterization mm Hg with that 
estimated by Doppler echocardiography (28 mm Hg [23–32 
mm Hg]) in 131 patients was r=0.72, P<0.001, with Doppler 
estimate being 9 mm Hg (4–16 mm Hg) lower than the inva-
sive measure. Using suggested alternative criteria for pulmo-
nary hypertension (mPAP ≥20 mm Hg),9 132 patients (82%) 
could be regarded as having increased PAP.
The PAWP at rest ranged from 6 to 41 mm Hg (average 
16±7 mm Hg) and was >15 mm Hg in 74 patients (46%). 
Cardiac output was measured in 157 subjects and ranged from 
2.2 to 12.3 L/min (cardiac index 1.0–5.4 L/min per meter 
square), normal (>5.0 L/min) in 73 patients, and reduced 
(<3.0 L/min) in 5 patients.
Relation of mPAP to Clinical Variables
Compared with patients with normal mPAP (<25 mm Hg), the 
82 patients with pulmonary hypertension (mPAP ≥25 mm Hg) 
were older (61.4 versus 56.9 years; P=0.006), with higher body 
mass index (33.2 versus 28.6 kg/m2; P<0.001), maximum LV 
wall thickness (20.0 versus 18.6 mm; P=0.024), and left atrial 
volume index (45 versus 41 mL/m2; Table 2). Clinically mean-
ingful differences between the groups were not identified for 
RV diameter (36 mm [32–42 mm] versus 37 mm [34–42] mm; 
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P=0.29) or RV fractional area change (48 [45–51] versus 46 
[42–50] % change; P=0.023). The prevalence of LGE did not 
differ between the HCM patients with pulmonary hypertension 
compared with those without pulmonary hypertension (51% 
versus 55%; P=0.51). In addition, among patients with LGE, 
there was no significant relationship between extent of LGE 
and mPAP (r=0.006; P=0.95). The mPAP was higher in alcohol 
septal ablation patients than in myectomy patients (30 mm Hg 
[23–41 mm Hg] versus 24 mm Hg [20–29 mm Hg]; P<0.02).
Comorbidities that have been associated with pulmonary 
hypertension, including chronic obstructive pulmonary dis-
ease, obstructive sleep apnea, history of pulmonary embolism, 
connective tissue, and interstitial lung diseases, were present 
in 32 patients (20%) and were more common in those with 
mPAP ≥25 mm Hg than in patients with mPAP <25 mm Hg 
(27% versus 13%; P=0.03).
Evidence for Precapillary Pulmonary Hypertension 
or Pulmonary Arterial Hypertension
A subgroup of 9 patients (11%) differed from other study 
patients with pulmonary hypertension by virtue of normal 
Table 1. Clinical, Echocardiographic, and Hemodynamic 
Characteristics in 162 Patients With Obstructive HCM
General Characteristics
Age, y 59.2 (10.5)
Male sex, n (%) 79 (49)
BMI, kg/m2 30.9±6.9
Atrial fibrillation, n (%) 36 (22)
Medications at RHC, n (%)
  β-blockers 135 (83)
  Calcium-channel blockers 49 (30)
  Disopyramide 20 (12)
  Diuretics 39 (24)
Echocardiographic variables
  Peak LVOT gradient, mm Hg 90 [70–110]
  LVEF, % 65 [61–70]
  Maximum LV wall thickness, mm 19.3±3.9
  LV end-diastolic volume index,  
mL/m2
51 [43–59]
  MR moderate or severe, n (%) 30 (19)
  Left atrial volume index, mL/m2 42 [36–52]
  Medial E/e′>15, n (%) 108 (72)
  RV diameter, mm 37 [33–42]
  RV diameter >42 mm, n (%) 36 (22)
  RV fractional area change, % 47 [43–51]
  Peak tricuspid annulus S′ velocity*, 
cm/s
12.3 [11.0–14.0]
Hemodynamic variables
  PASP, mm Hg 41 [31–46]
  Mean PAP, mm Hg 25 [20–31]
  mPAP ≥25 mm Hg, n (%) 82 (51)
  mPAP 25–34 mm Hg, n (%) 53 (33)
  mPAP 35–44 mm Hg, n (%) 17 (11)
  mPAP ≥45 mm Hg, n (%) 12 (7)
  Right atrial pressure, mm Hg 7 [5–10]
  TPG, mm Hg 10 [7–13]
  TPG>12 mm Hg, n (%) 45 (28)
  PAWP, mm Hg 15 [12–20]
  PAWP >15 mm Hg, n (%) 74 (46)
  PVR, WU 1.89 [1.31–2.57]
  PVR >3.0 WU, n (%) 34 (21)
  CI, L/min per m2 2.51 [2.17–2.91]
  DPG ≥7 mm Hg, % 11 (7%)
For continuous data, results are reported as mean±SD. For data not distributed 
normally, results are reported as median (interquartile range). BMI indicates body 
mass index; CI, cardiac index; DPG, diastolic pressure gradient; LV, left ventricular; 
EF, ejection fraction; LVOT, left ventricular outflow tract; MR, mitral regurgitation; 
mPAP, mean pulmonary artery pressure; PAP, pulmonary artery pressure; PASP, 
pulmonary artery systolic pressure; PAWP, pulmonary artery wedge pressure; 
PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right 
ventricular; TPG, transpulmonary gradient; and WU, Wood units.
*Data were available for 92 of 162 patients (57%).
Figure 1. Distribution of mean pulmonary artery pressure (mPAP) 
in 162 patients with hypertrophic cardiomyopathy undergoing 
cardiac catheterization.
Figure 2. Mean pulmonary artery pressure (mPAP) does not cor-
relate with resting left ventricular outflow tract (LVOT) gradient in 
patients with obstructive hypertrophic cardiomyopathy.
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PAWP (≤15 mm Hg) in the presence of pulmonary vascular 
resistance >3.0 WU. The majority did not have concomitant 
clinical comorbidites or significant mitral regurgitation that 
could be responsible for increased PAPs. These 9 patients 
were older (68 versus 61 years; P=0.042) than others with 
pulmonary hypertension, but did not significantly differ from 
other pulmonary hypertension patients with respect to sex, LV 
outflow gradient, ejection fraction, maximum wall thickness, 
left atrial volume, and mPAP. However, a higher percentage 
of patients in this subgroup had enlargement of the RV cavity, 
defined by a diameter >42 mm (56% versus 20%; P=0.03), 
and RV systolic function was decreased (43 [40–46] versus 48 
[45–51] versus % fractional area change; P=0.009) compared 
with other patients with HCM (Table 3).
Septal Reduction Therapy and Outcome
Preoperative or preprocedural outflow gradients at rest 
(n=125) or with physiological provocation (n=37) ranged 
from 50 to 160 mm Hg (median, 90 mm Hg). Postoperatively, 
at rest, each had marked reduction or obliteration of mitral 
valve systolic anterior motion with zero gradient or a gradient 
estimated <30 mm Hg with Doppler echocardiography. Over a 
median follow-up of 327 days after myectomy or ablation, the 
vast majority of patients with preoperative pulmonary hyper-
tension were asymptomatic or mildly symptomatic (n=71/77; 
92%), similar to patients without pulmonary hypertension 
(n=77/80; 96%).
In addition, myectomy patients with severe pulmonary 
hypertension (mPAP ≥36 mm Hg) preoperatively (n=12) 
did not differ significantly compared with patients with 
mild to moderate pulmonary hypertension (mPAP <36 
mm Hg) preoperatively (n=104) for relevant postoperative 
complications, including stroke, myocardial infarction, 
major bleeding, respiratory failure, acute renal failure or 
death; prolonged intravenous inotrope use postoperatively 
≥3 days; or prolonged inpatient hospitalization (≥10 days) 
(2/12 [16.7%] versus 14/104 [13.5%]; P=0.67). The 1 post-
operative death in the group with pulmonary hypertension 
occurred in a 59-year-old woman who died from acute 
respiratory failure with severe pulmonary hypertension 
(mPAP=65 mm Hg). A second postoperative death occurred 
in a 50-year-old man because of mesenteric ischemia 
(mPAP=22 mm Hg).
Discussion
With the decrease in sudden death events in HCM because 
of penetration of the implantable cardioverter defibrillator 
into the management of this patient population, heart fail-
ure, and its consequences has assumed an enlarging pro-
file.10,11 The mechanisms of advanced heart failure in HCM 
are diverse, including a minority of patients who evolve to 
the end-stage with or without systolic dysfunction.10,12 How-
ever, in the vast majority of patients with progressive drug-
refractory disability, symptoms are related to dynamic LV 
outflow tract obstruction resulting in high LV pressure and 
wall stress.
The role of pulmonary hypertension in this HCM-related 
heart failure scenario is unresolved, with some investigators 
attributing deleterious clinical consequences (including an 
Table 2. Clinical and Hemodynamic Characteristics With 
Respect to mPAP
 
mPAP <25 
mm Hg (n=80)
mPAP≥25 
mm Hg (n=82)
P Value
General characteristics
  Age, y 56.9 (9.6) 61.4 (10.8) 0.006
  Male sex, n (%) 42 (52.5) 37 (45.1) 0.43
  BMI, kg/m2 28.6±5.3 33.2±7.5 <0.001
  NYHA class III or IV at 
RHC, n (%)
55 (68.8) 64 (78.1) 0.21
  Atrial fibrillation, n (%) 17 (21.3) 19 (23.2) 0.92
Echocardiography
  Peak LVOT gradient, 
mm Hg
90 [75–105] 88 [70–110] 0.66
  LVEF, % 66 [61–71] 64 [60–69] 0.14
  Maximum wall 
thickness, mm
18.6±3.8 20.0±3.9 0.024
  Moderate or severe 
MR, n (%)
12 (15) 18 (22) 0.31
  Left atrial volume 
index, mL/m2
41 [35–48] 45 [38–54] 0.017
  Left atrial volume 
index ≥34 mL/m2, 
n (%)
64 (80) 75 (92) 0.062
  LV diastolic E/A ratio 
≥2, n (%)
1 (1.3) 9 (11.4) 0.023
  LV diastolic medial 
E/e’>15, n (%)
46 (60.5) 62 (83.8) 0.002
  RV diameter, mm 36 [32–42] 37 [34–42] 0.29
  RV diameter >42 mm, 
n (%)
16 (20) 20 (24) 0.57
  RV fractional area 
change, %
48 [45–51] 46 [42–50] 0.023
Cardiopulmonary hemodynamics
  PASP, mm Hg 31 [28–34] 46 [41–56] <0.001
  mPAP, mm Hg 20 [18–22] 31 [28–38] <0.001
  Right atrial pressure, 
mm Hg
6 [3- 8] 9 [7–13] <0.001
  TPG, mm Hg 8 [7–10] 13 [9–16] <0.001
  TPG>12 mm Hg, n (%) 4 (5) 41 (50) <0.001
  PAWP, mm Hg 12 [10–14] 20 [16–24] <0.001
  PAWP>15 mm Hg, 
n (%)
8 (10.0) 66 (80.5) <0.001
  PVR, WU 1.59 [1.23–2.13] 2.45 [1.66–3.26] <0.001
  CI, L/min per m2 2.52 [2.21–2.96] 2.51 [2.16–2.85] 0.55
  DPG ≥7 mm Hg, % 0 (0) 12 (15) <0.001
For continuous data, results are reported as mean±SD. For data not 
distributed normally, results are reported as median (interquartile range). BMI 
indicates body mass index; CI, cardiac index; DPG, diastolic pressure gradient; 
LV, left ventricular; EF, ejection fraction; LVOT, left ventricular outflow tract; 
mPAP, mean pulmonary artery pressure; MR, mitral regurgitation; NYHA, New 
York Heart Association; PASP, pulmonary artery systolic pressure; PAWP, 
pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; RHC, 
right heart catheterization; RV, right ventricle; TPG, transpulmonary gradient; 
and WU, Wood units.
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increase in all-cause mortality) to elevations in pulmonary 
pressures estimated noninvasively with Doppler echocardiog-
raphy.4 On the contrary, we have the unique opportunity to 
report here the role of pulmonary hypertension in advanced 
heart failure with cardiopulmonary hemodynamics measured 
directly at cardiac catheterization.13 The study group com-
prises a consecutive cohort of patients undergoing surgical 
septal myectomy (or alcohol septal ablation) to relieve out-
flow tract obstruction and mitigate heart failure symptoms, at 
a single HCM tertiary referral institution.
We encountered a high frequency of elevated PAPs in 
about one-half of our study patients using the conventional cri-
terion of mPAP ≥25 mm Hg, including 15% of these patients 
who had particularly marked PAP >45 mm Hg. Furthermore, 
recent data in large non-HCM populations suggest that mPAP 
≥20 mm Hg is independently associated with adverse clinical 
outcome; using this cutoff value, >80% of our HCM patients 
would be considered to have pulmonary hypertension.9
Given the high frequency of pulmonary hypertension in 
this cohort (including moderate to severe levels), we can-
not exclude the novel possibility that increased pulmonary 
pressures played a role in producing advanced heart fail-
ure symptoms, in association with LV outflow obstruction. 
Notably, we found little evidence that abnormal cardio-
pulmonary hemodynamics, including increased PAP, were 
associated with adverse clinical consequences in patients 
undergoing septal myectomy (or alcohol septal ablation) 
procedures, perioperatively, or over follow-up. For example, 
>95% of our patients reported improvement in symptoms 
from New York Heart Association functional class III/IV 
to absent or only mild symptoms. However, the subgroup 
of patients with severe preoperative pulmonary hyperten-
sion was no more likely to experience many clinically rel-
evant adverse postoperative measures such as major surgical 
complications, prolonged use of intravenous inotropes, or 
extended duration of hospitalization compared with patients 
with mild or moderate pulmonary hypertension. One excep-
tion was a 59-year-old woman who died postoperatively 
because of respiratory arrest with severe preoperative pul-
monary hypertension (mPAP, 65 mm Hg). Whether pulmo-
nary hypertension was directly responsible for demise of this 
patient remains unresolved.
Overall, our observations also suggest that it is unneces-
sary to consider specific therapeutic pharmacological inter-
ventions to mitigate pulmonary hypertension preoperatively 
in patients with HCM undergoing surgical or percutaneous 
interventions. Therefore, although pulmonary hypertension 
is an established risk factor for adverse outcome in patients 
undergoing most forms of cardiac surgery,14 our data would 
suggest that septal myectomy may be an exception in this 
regard. Nevertheless, the data reported here do not exclude the 
possibility that pulmonary hypertension could otherwise have 
a significant role in the presentation, clinical consequences, 
and natural history of HCM, thereby underscoring the poten-
tial value of continued investigations.
Heart failure in HCM differs fundamentally in expres-
sion from that of ischemic heart disease or other nonischemic 
cardiomyopathies by virtue of its characteristic association 
with preserved ejection fraction and normal cardiac output. 
Table 3. Clinical Characteristics in 9 Patients With 
Hemodynamics Consistent With Precapillary PH
 
Precapillary  
PH or PAH (n=9)
Clinical characteristics
  Age, y 68.3 (10.3)
  Men, n (%) 4 (44)
  BMI, kg/m2 29.3±3
  Active smokers, n (%) 1 (11)
  NYHA class III or IV, n (%) 8 (89)
  Obstructive CAD, n (%) 3 (33)
  Hypertension, n (%) 2 (22)
  Any PH-related comorbidity, n (%) 1 (11)
Medications at RHC, n (%)
  β-blockers 8 (89)
  Calcium-channel blockers 3 (33)
  Disopyramide 0 (0)
  Diuretics 3 (33)
Echocardiography
  LVOT gradient at rest, mm Hg 70 [60–80]
  Peak LVOT gradient, mm Hg 80 [70–110]
  LVEF, % 63 [61–72]
  Maximum LV thickness, mm 20±4
  MR moderate or severe, n (%) 4 (44)
  LA volume index, mL/m2 46 [41–59]
  RV diameter (mm) 43 [33–43]
  RV diameter >42 mm, % 56
  RV fractional area change (%) 43 [40–46]
Cardiopulmonary hemodynamics
  mPAP, mm Hg 28 [27–34]
  TPG, mm Hg 18 [14–19]
  PAWP, mm Hg 13 [12–14]
  PVR, WU 3.44 [3.27–4.75]
  CI, L/m2 2.07 [1.92–2.37]
  DPG ≥7 mm Hg, % 4 (44)
Invasive therapy
  Surgical myectomy n=5
  Alcohol septal ablation n=4
  Major complications n=0
  Postoperative NYHA I n=7
  Postoperative NYHA II n=2
For normally distributed data, results are reported as mean±SD. For data not 
distributed normally, results are reported as median (interquartile range). BMI 
indicates body mass index; CAD, coronary artery disease; CI, cardiac index; 
DPG, diastolic pressure gradient; LV, left ventricular; EF, ejection fraction; 
LVOT, left ventricular outflow tract; mPAP, mean pulmonary artery pressure; 
MR, mitral regurgitation; NYHA, New York Heart Association; PAH, pulmonary 
arterial hypertension; PAP, pulmonary artery pressure; PASP, pulmonary artery 
systolic pressure; PAWP, pulmonary artery wedge pressure; PH, pulmonary 
hypertension; PVR, pulmonary vascular resistance; TPG, transpulmonary 
gradient; and WU, Wood units.
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An uncommon exception to this construct in HCM is the 
end-stage phase with impaired systolic function because of 
extensive myocardial scarring.1,2 The mechanism by which 
increased PAPs develop and potentially contribute to heart 
failure symptoms in HCM patients with LV outflow tract 
obstruction remains incompletely resolved. However, it is 
likely that on some of our patients, the outflow tract gradient 
and increased LV cavitary pressure, and possibly mitral regur-
gitation, may cause left atrial pressure to increase (inferred 
from the increased PAWP), and as a consequence raised PAPs, 
which in turn contributed to advanced heart failure symptoms 
(Figure 3).
On the contrary, we should emphasize that we found 
only an inconsistent relation between PAP and LV outflow 
tract gradient or mitral regurgitation, allowing for the pos-
sibility that in some patients, pulmonary hypertension rep-
resented intrinsic pulmonary vascular disease independent 
of mechanical left-sided obstruction and heart failure.15 In 
this regard, we identified a subset of patients (≈10%) with 
pulmonary hypertension associated with increased pulmo-
nary vascular resistance, RV diameter, and diastolic pressure 
gradient gradient, but normal PAWP. This scenario raises 
the possibility of coexistent precapillary pulmonary hyper-
tension or pulmonary arterial hypertension in some patients 
Figure 3. Pulmonary hypertension (PH) and the pathophysiology of heart failure symptoms in obstructive hypertrophic cardiomyopathy 
(HCM). A, Our findings suggest that in patients with obstructive HCM referred for septal reduction therapy, PH is common and may be 
one pathophysiology underlying heart failure (HF) symptoms in this patient population. Analysis of invasive cardiopulmonary hemodynam-
ics before surgical myectomy or alcohol septal ablation suggests that PH is often associated with left atrial hypertension, which may be 
because of dynamic left ventricular outflow tract obstruction and mitral regurgitation. However, we also observed in some patients an 
increase in pulmonary artery pressure (PAP) without left atrial hypertension or other cardiopulmonary diseases commonly associated with 
PH, raising the possibility that intrinsic pulmonary vascular remodeling was present in this obstructive HCM patient subgroup. B, A signifi-
cant difference in clinical response to septal reduction therapy with surgical myectomy or alcohol septal ablation (ASA) was not observed 
in patients with preprocedural PH compared with patients with normal preprocedural mean PAP (mPAP). LVOT indicates left ventricular 
outflow tract; PAH, pulmonary arterial hypertension; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; 
NYHA, New York Heart Association; and prC-PH, precapillary pulmonary hypertension. Reprinted from Nishimura et al16 with permission 
of the publisher. Copyright ©2003, American Heart Association.
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with HCM. However, confirmation and further characteriza-
tion of pulmonary vascular disease is needed in patients with 
HCM, which will likely require histopathologic analysis of 
pulmonary tissue acquired from such patients. This is par-
ticularly the case because left atrial enlargement, borderline 
abnormal PAWP, and diuretic use were observed for patients 
with HCM within this subgroup, suggesting that provocative 
maneuvers such as confrontational fluid challenge (which 
were not performed in this study) could unmask a contribu-
tion of left atrial hypertension to pulmonary hypertension in 
these patients.14
There are limitations to our study design that justify 
acknowledgment here. First, clinical care considerations 
did not allow us to routinely repeat cardiac catheterizations 
after surgery or alcohol ablation. The right heart catheteriza-
tion was performed by multiple proceduralists over the span 
of the study period, likely with some minor variability in 
measurements. However, a blinded review of the right heart 
catheterization tracings was performed for the precapillary 
pulmonary hypertension patients, and this analysis confirmed 
the accuracy of the reported values. In addition, the limited 
sample size of certain subgroups, such as subjects fulfilling 
hemodynamic criteria for pulmonary arterial hypertension, 
prevented a more detailed characterization of this phenotype. 
Furthermore, we have resisted solely reporting estimates of 
PAP with Doppler echocardiography postoperatively, given 
its relatively poor correlation with these measurements made 
directly at cardiac catheterization, as reported here and by 
other authors.17,18 Nevertheless, Mayo investigators using 
Doppler estimates both pre- and postoperatively showed that 
pulmonary hypertension was reversed by surgical myectomy 
in most patients with HCM.3 Finally, we are lacking complete 
data on other possible contributors to pulmonary hyperten-
sion, such as the response of mPAP and PAWP to exercise 
or findings from additional diagnostic testing for the evalu-
ation of pulmonary hypertension, which could be of value in 
achieving a better understanding of pathophysiology in our 
novel patient subset considered consistent with pulmonary 
arterial hypertension.19,20
The number of patients with HCM who underwent 
genetic testing in this cohort was too small to determine 
whether specific sarcomere mutations were associated with 
pulmonary hypertension. However, given the large number 
of individual mutations now associated with HCM (>1800), 
many of which are unique to 1 family (private), it is highly 
unlikely we would have identified a relationship between 
sarcomere mutation and pulmonary hypertension, similar to 
previous observations that have demonstrated no clear asso-
ciation between genotype and other aspects of the HCM phe-
notype (ie, LV wall thickness, extent of fibrosis, obstruction) 
or outcome.21
In conclusion, pulmonary hypertension is common 
in obstructive HCM patients with severe heart failure. 
Unexpectedly, our data did not recognize elevated pulmo-
nary pressures as a risk factor for adverse clinical outcome 
among patients with obstructive HCM undergoing surgical 
myectomy (or alcohol septal ablation) or do they suggest that 
such patients require intervention to normalize pulmonary 
pressures. Nevertheless, this analysis uncovered the distinct 
possibility of a new subset of patients with HCM character-
ized by pulmonary vascular disease.
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CLINICAL PERSPECTIVE
Since the initial description of hypertrophic cardiomyopathy (HCM), left ventricular outflow tract obstruction has been 
considered a prominent determinant of heart failure. However, the clinical profile and contribution of pulmonary hyperten-
sion to limiting symptoms and management of patients with obstructive HCM is incompletely understood. In this report, we 
analyzed invasive cardiopulmonary hemodynamic and echocardiography data from 162 consecutive patients with obstruc-
tive HCM referred for surgical septal myectomy. Pulmonary hypertension, defined as a mean pulmonary artery pressure 
≥25 mm Hg on cardiac catheterization, was present in a majority of patients with HCM and was moderate or severe in 20%. 
Pulmonary artery pressure did not correlate with magnitude of left ventricular outflow tract gradient and was observed com-
monly in patients with normal pulmonary artery wedge pressure. In addition, in 11% of patients, cardiopulmonary hemo-
dynamics consistent with precapillary pulmonary hypertension or pulmonary arterial hypertension were present, suggesting 
that in a subgroup of patients, pulmonary hypertension may be a primary disease manifestation and not because of left heart 
disease. However, compared with patients with normal pulmonary artery pressure, pulmonary hypertension was not associ-
ated with a significant difference in clinical response or short-term outcome after surgical myectomy. Overall, our study 
shows that pulmonary hypertension is common and may be a novel contributor to heart failure in patients with obstructive 
HCM but does not seem to influence surgical risk or clinical improvement from myectomy.
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